BFC Planning’s Dr. Reddy's Laboratories RDY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$69.4K Hold
5,500
– – ﹤0.01% 1405
2026
Q2
$79.7K Buy
5,500
+500
+10% +$6.75K ﹤0.01% 1328
2026
Q1
$69.2K Hold
5,000
– – ﹤0.01% 1226
2025
Q4
$70.2K Hold
5,000
– – ﹤0.01% 1227
2025
Q3
$69.9K Hold
5,000
– – 0.01% 1049
2025
Q2
$75.2K Hold
5,000
– – 0.01% 984
2025
Q1
$66K Hold
5,000
– – 0.01% 1003
2024
Q4
$79K Hold
5,000
– – 0.01% 954
2024
Q3
$79.4K Buy
+5,000
New +$80.5K 0.01% 959

Other funds holding RDY

BFC Planning's RDY Position: Q3 2026 in Review

BFC Planning held its Dr. Reddy's Laboratories (RDY) position steady in Q3 2026 at 5,500 shares worth $69.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1405.

BFC Planning first reported a position in RDY in Q3 2024 and has held it in 9 quarters since. The position peaked at $79.7K in Q2 2026. 186 funds tracked by Wall St. Rank hold RDY as of Q3 2026.

  • BFC Planning held 5,500 shares of Dr. Reddy's Laboratories worth $69.4K as of Q3 2026.
  • BFC Planning left its Dr. Reddy's Laboratories share count unchanged in Q3 2026.
  • Dr. Reddy's Laboratories made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1405 holding.
  • BFC Planning first reported a position in Dr. Reddy's Laboratories in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Dr. Reddy's Laboratories position peaked at $79.7K in Q2 2026.
  • 186 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.